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The three major isoforms of RAS (H-, K- and N-RAS) differ only in the last 25 amino acids which are the site 
of different post-translational modifications that lead to localization in diverse plasma membrane 
microdomains and activation of alternative pathways of signal transduction. This might explain, at least in 
part, the different biological effects of the RAS isoforms in the cells. RAS mutations are a common event in 
several tumours and in colorectal carcinomas the genetic alteration is a point mutation in codons 12 or 13 
of K-RAS. These mutations lead to a constitutively active protein by inactivating its GTPase activity. To shed 
more light on the molecular mechanisms responsible for the different effects of RAS mutations, we have 
used stable clones of HT-29 (a human colorectal adenocarcinoma cell line in which the endogenous RAS 
genes are wild type) transfected with cDNAs codifying: K-RASG12V (clone K12) and K-RASG13D (clone K13) 
under the control of a Mifepristone-inducible promoter [GeneSwitchTM System (Invitrogen)]. We found 
that the two mutated isoforms of K-RAS  induce different effects on the growth rate and on the cell cycle 
and a similar increase in the p21
CIP1/WAF1
 expression. The increase of p21
CIP1/WAF1
 protein expression and the 
effects on the cell cycle are not reduced by treatment with MEK or/and PI3K inhibitors. K-RASG12V and K-
RASG13D also induce differential effects on the pro-apoptotic (MST2-RASSF1A-LATS1) and the anti-
apoptotic (MST2-RAF-1) pathways. Finally, the data show an increase in total cell death in both induced 
clones, but K-RASG12V induce a significant increase in apoptosis while K-RASG13D in necrosis; the cytotoxic 
effect observed in induced K13 cells decreases in starved conditions.  
 
